CervoMed to Participate in the BIO CEO and Investor Conference
CervoMed to Participate in the BIO CEO and Investor Conference
BOSTON, Feb. 21, 2024 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical stage company focused on developing treatments for degenerative diseases of the brain, today announced that Company's Management will present at the BIO CEO and Investor Conference on February 26, 2024, being held in New York, NY and participate in one-on-one investor meetings.
波士頓，2024年2月21日（環球新聞社）——專注於開發腦退行性疾病治療方法的臨床階段公司CervoMed Inc.（納斯達克股票代碼：CRVO）今天宣佈，公司管理層將出席2024年2月26日在紐約舉行的BIO首席執行官和投資者會議，並參加一對一的投資者會議。
Presentation Details
Format: Corporate presentation
Date: Monday, February 26, 2024
Time: 2:00 PM ET
演示詳情
格式：企業演示文稿
日期：2024 年 2 月 26 日星期一
時間：美國東部時間下午 2:00
To learn more about the BIO CEO and Investor Conference please visit
要了解有關BIO首席執行官和投資者會議的更多信息，請訪問
About CervoMed
CervoMed Inc. is a clinical-stage company focused on developing treatments for degenerative diseases of the brain. The Company is currently developing neflamapimod, an investigational orally administered small molecule brain penetrant that inhibits p38MAP kinase alpha (p38a). Neflamapimod has the potential to treat synaptic dysfunction, the reversible aspect of the underlying neurodegenerative processes that cause disease in dementia with Lewy bodies (DLB) and certain other major neurological disorders. Neflamapimod is currently being evaluated in a Phase 2b study in patients with DLB.
關於 CervoMed
CervoMed Inc. 是一家處於臨床階段的公司，專注於開發腦退行性疾病的治療方法。該公司目前正在開發奈弗拉匹莫德，這是一種研究中的口服小分子腦穿透劑，可抑制p38map激酶α激酶（p38a）。奈弗拉匹莫德有可能治療突觸功能障礙，突觸功能障礙是潛在神經退行過程的可逆方面，可導致路易體癡呆（DLB）和某些其他主要神經系統疾病。奈弗拉匹莫德目前正在一項針對DLB患者的2b期研究中進行評估。
Investor Contact:
PJ Kelleher
LifeSci Advisors
Investors@cervomed.com
617-430-7579
投資者聯繫人：
PJ Kelleher
生命科學顧問
Investors@cervomed.com
617-430-7579
譯文內容由第三人軟體翻譯。